Testing QI-019A for multiple myeloma that came back
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a new drug called QI-019A for people whose multiple myeloma has returned or stopped responding to at least two prior treatments. The goal is to see if it is safe and if it can help control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have multiple myeloma that got worse during or within a year after your last anti-myeloma treatment.
- You have tried at least two different anti-myeloma treatments, each for at least one full cycle.
- Your disease can be measured with a blood or urine test (M protein, free light chains).
- You are up and about (ECOG score 0-2) and expected to live at least 3 more months.
- Your blood counts, kidney, liver, heart, and lung functions are within safe limits as assessed by tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage trial tests a new drug called QI-019B in patients whose multiple myeloma (a blood cancer) has stopped responding to standard treatments. The study checks if QI-019B is safe and whether it helps slow or stop the cancer's growth.
This trial tests a new drug called CM336 for people with multiple myeloma that has come back or stopped responding to at least two previous treatments. It aims to see if CM336 can help control the disease.
This early-stage trial tests a new therapy called RN9101 for multiple myeloma that has come back or stopped responding to previous treatments. The drug targets a specific protein (BCMA) on myeloma cells and may help patients whose disease has progressed despite earlier therapies.
This trial tests a new treatment called ESO-T01 for people with multiple myeloma that has come back or is not responding to at least two prior therapies. It aims to see if this therapy is safe and can help control the disease.
This trial tests a new injectable treatment for people with multiple myeloma that has come back or not responded to previous therapies. It aims to see if the drug is safe and effective.
This early-stage trial tests a new drug called DQ1001 for multiple myeloma that has stopped responding to prior treatments. The drug is designed to target specific markers on myeloma cells and may help patients whose cancer has come back or become resistant to previous therapies.
Hear when a new Multiple Myeloma (MM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.